Browse All

Current Filters

CLEAR FILTER x

TITLE

Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis

Author:Cerqueira, Joao   Berthele, Achim   Cree, Bruce   Filippi, Massimo   Pardo, Gabriel   Pearson, Owen   Traboulsee, Anthony   Ziemssen, Tjalf   Vollmer, Timothy   Bernasconi, Corrado   Mandel, Corey   Kulyk, Inessa   Chognot, Cathy   Schneble, Hans-Martin   Prajapati, Kalpesh   Havrdova, Eva   

Session Name:S46: MS Therapeutics and Clinical Decision Making  

Topic:MS and Inflammatory Disease  

Program Number:S46.002  

Author Institution:2CA-Clinical Academic Centre Braga, Portugal Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga, Portugal, Lisbon, Portugal  School of Medicine, Technical University of Munich, Munich, Germany, Muenchen, Germany  University of California San Francisco, San Francisco, CA, USA, San Francisco, CA  IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy  Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK  Morriston Hospital, Swansea, UK, Swansea, United Kingdom  University of British Columbia, Vancouver, BC, Canada, Vancouver, BC, Canada  Dresden University of Technology, Dresden, Germany, Dresden, Germany  University of Colorado Denver, Denver, CO, USA, Aurora, CO  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Genentech, Inc., San Francisco, CA, USA, South San Francisco, CA  IQVIA Solutions, Inc., Amsterdam, The Netherlands, Amsterdam, Netherlands  General University Hospital and Charles University, Prague, Czech Republic, Praha 2, Czech Republic  

Tracking the immune response to SARS-CoV-2 mRNA booster vaccination in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS clinical trial)

ILLUMINATE: Design of a Real-World, Non-Interventional Study Evaluating the Usability and Value of Integrated Digital Solutions for Routine Care of Patients with Multiple Sclerosis

Final results of the PANGAEA 2.0 study: Treatment benefits of fingolimod for active RRMS patients switching from other DMTs

Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS

Author:Alvarez, Enrique   Kuhle, Jens   Kappos, Ludwig   Ziemssen, Tjalf   Arnold, Douglas   Cross, Anne   Boer, Ibolya   Das Gupta, Ayan   Hu, Xixi   Kukkaro, Petra   Kieseier, Bernd   Zielman, Ronald   Hauser, Stephen   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.013  

Author Institution:Department of Neurology, Rocky Mountain MS Center at the University of Colorado, Aurora, CO  Neurology, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland  Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl Gustav Carus, Dresden, Germany  McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University and NeuroRx Research, Montreal, QC, Canada  Washington University School of Medicine, Saint Louis, MO  Novartis Pharma AG, Basel, Switzerland  Novartis Healthcare, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V., Amsterdam, Netherlands  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA